Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between Campath and Lemtrada

Results for the following 2 drugs:
Campath (alemtuzumab)
Lemtrada (alemtuzumab)

Interactions between your drugs

There were no interactions found in our database between Campath and Lemtrada - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Campath

A total of 314 drugs (907 brand and generic names) are known to interact with Campath.

Lemtrada

A total of 314 drugs (907 brand and generic names) are known to interact with Lemtrada.

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Immunomodulators for multiple sclerosis

Therapeutic duplication

The recommended maximum number of medicines in the 'immunomodulators for multiple sclerosis' category to be taken concurrently is usually one. Your list includes one medicines belonging to the 'immunomodulators for multiple sclerosis' category:

  • alemtuzumab
  • alemtuzumab

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Duplication

CD52 monoclonal antibodies

Therapeutic duplication

The recommended maximum number of medicines in the 'CD52 monoclonal antibodies' category to be taken concurrently is usually one. Your list includes one medicines belonging to the 'CD52 monoclonal antibodies' category:

  • alemtuzumab
  • alemtuzumab

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide